Which alternative treatment for PAH does not require an intravenous catheter?

The correct choice showcases an alternative treatment for pulmonary arterial hypertension (PAH) that can be administered without the need for intravenous catheters. Treprostinil, when given as a subcutaneous injection, bypasses the complexities and potential complications associated with intravenous therapy, such as catheter-related infections, thrombosis, and maintenance challenges.

In the case of inhaled iloprost and oral sildenafil, both are effective treatments for PAH but differ in their administration routes. Iloprost, delivered via inhalation, requires specific nebulization equipment, but it does not rely on intravenous access. Meanwhile, riociguat is an oral medication, intended for PAH management, and likewise does not necessitate intravenous administration.

Overall, the main point is that treprostinil can be administered via subcutaneous injection, providing a less invasive option while still effectively managing PAH symptoms without the potential complications associated with intravenous catheters.